Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for diabetes and obesity.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies. The company is one of the best stocks to buy in the pharmaceutical industry, and management expects a 32% revenue growth in fiscal 2025.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and currently trading at $756.99. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly dropped by as much as 8% and ended the day down around 6%. Year-to-date, share prices are down about 1.4%.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep correction. Lilly is by no means in bad shape, but because the stock's price has become so inflated in recent years, so have expectations.